Suivre
Houssiau FA
Houssiau FA
Professeur; IREC, SSS, Université catholique de Louvain
Adresse e-mail validée de uclouvain.be
Titre
Citée par
Citée par
Année
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
R Cervera, JC Piette, J Font, MA Khamashta, Y Shoenfeld, MT Camps, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2002
25492002
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients
R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ...
Medicine 82 (5), 299-308, 2003
17622003
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
A Fanouriakis, M Kostopoulou, A Alunno, M Aringer, I Bajema, JN Boletis, ...
Annals of the rheumatic diseases 78 (6), 736-745, 2019
17342019
Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients
R Cervera, MA Khamashta, J Font, GD SEBASTIANI, A Gil, P Lavilla, ...
Medicine 72 (2), 113-124, 1993
13371993
Immunosuppressive therapy in lupus nephritis: the Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide
FA Houssiau, C Vasconcelos, D D'Cruz, GD Sebastiani, ER Garrido, ...
Arthritis & Rheumatism 46 (8), 2121-2131, 2002
12942002
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of …
GK Bertsias, M Tektonidou, Z Amoura, M Aringer, I Bajema, JHM Berden, ...
Annals of the rheumatic diseases 71 (11), 1771-1782, 2012
12242012
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
R Cervera, R Serrano, GJ Pons-Estel, L Ceberio-Hualde, Y Shoenfeld, ...
Annals of the rheumatic diseases 74 (6), 1011-1018, 2015
1088*2015
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including …
GK Bertsias, JPA Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, ...
Annals of the rheumatic diseases 67 (2), 195-205, 2008
10252008
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
B Klein, XG Zhang, M Jourdan, J Content, F Houssiau, L Aarden, ...
10021989
Interleukin‐6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides
FA Houssiau, JP Devogelaer, JV Damme, CND Deuxchaisnes, JV Snick
Arthritis & Rheumatism: Official Journal of the American College of …, 1988
9871988
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
RF Van Vollenhoven, M Mosca, G Bertsias, D Isenberg, A Kuhn, ...
Annals of the rheumatic diseases 73 (6), 958-967, 2014
7872014
Two-year, randomized, controlled trial of belimumab in lupus nephritis
R Furie, BH Rovin, F Houssiau, A Malvar, YKO Teng, G Contreras, ...
New England Journal of Medicine 383 (12), 1117-1128, 2020
6662020
2019 update of the joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the …
A Fanouriakis, M Kostopoulou, K Cheema, HJ Anders, M Aringer, ...
Annals of the rheumatic diseases 79 (6), 713-723, 2020
6572020
Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients
R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ...
Medicine 78 (3), 167-175, 1999
5931999
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide
FA Houssiau, C Vasconcelos, D D’Cruz, GD Sebastiani, ...
Annals of the rheumatic diseases 69 (01), 61-64, 2010
5892010
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
FA Houssiau, D D'Cruz, S Sangle, P Remy, C Vasconcelos, R Petrovic, ...
Annals of the rheumatic diseases 69 (12), 2083-2089, 2010
5692010
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long‐term followup of patients in the Euro‐Lupus Nephritis Trial
FA Houssiau, C Vasconcelos, D D'Cruz, GD Sebastiani, ...
Arthritis & rheumatism 50 (12), 3934-3940, 2004
4652004
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus
TRDJ Radstake, O Gorlova, B Rueda, JE Martin, BZ Alizadeh, ...
Nature genetics 42 (5), 426-429, 2010
4482010
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo …
DJ Wallace, K Kalunian, MA Petri, V Strand, FA Houssiau, M Pike, ...
Annals of the rheumatic diseases 73 (1), 183-190, 2014
4012014
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
R Van Vollenhoven, A Voskuyl, G Bertsias, C Aranow, M Aringer, ...
Annals of the rheumatic diseases 76 (3), 554-561, 2017
3652017
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20